Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

Tivozanib

a115e391-00ad-50a6-bfbf-c30714db0b92 · FDA Approved · targets KDR_VEGFR2

Tivozanib

MeasuredReference

Tivozanib targets RET, C_KIT, KDR_VEGFR2. Strongest hallmark effect: tumor promoting inflammation.

Top hallmarks

  • tumor promoting inflammation4.5k
  • evading apoptosis3.6k
  • proliferation3.4k

Top pathways disrupted

  • apical junction9.9k
  • allograft rejection9.3k
  • pi3k akt mtor signaling9.1k

Resistance landscape — Tivozanib

MeasuredReference

10 known oncogenic variants exist on Tivozanib's top targets — see detail for inhibition impact.

Open in new tab